Loading

Please wait...

Briviact

Generic Name: brivaracetam (oral/injection) (BRIV a RA se tam)
Brand Names: Briviact
Briviact (brivaracetam) is used to treat partial onset seizures in patients with epilepsy. Includes Briviact side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Briviact

Set your location
for drug prices near you

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Briviact (brivaracetam) is an anti-epileptic drug, also called an anticonvulsant. Briviact is used to treat partial onset seizures in people with epilepsy. Briviact oral is for use in adults and children who are at least 4 years old. The injection is for use in people who are at least 16 years old. Some people have thoughts about suicide while taking seizure medicine. Stay alert to changes in your mood or symptoms. Report any new or worsening symptoms to your doctor. You should not use Briviact if you are allergic to brivaracetam. Learn more

Briviact Side Effects

Briviact Side Effects

Note: This document contains side effect information about brivaracetam. Some of the dosage forms listed on this page may not apply to the brand name Briviact.

In Summary

Common side effects of Briviact include: acute psychosis, balance impairment, dizziness, drowsiness, fatigue, sedated state, abnormal behavior, abnormal gait, aggressive behavior, agitation, anxiety, apathy, asthenia, ataxia, depressed mood, depression, hallucination, hypersomnia, lacrimation, lethargy, nervousness, nystagmus disorder, paranoid ideation, psychomotor agitation, vertigo, irritability, emotional lability, malaise, and restlessness. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to brivaracetam: oral solution, oral tablet

Other dosage forms:

  • intravenous solution

Along with its needed effects, brivaracetam (the active ingredient contained in Briviact) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking brivaracetam:

More common

  • Anxiety
  • changes in behavior
  • chest pain or discomfort
  • deep or fast breathing with dizziness
  • dizziness or lightheadedness
  • double vision
  • drowsiness
  • dry mouth
  • general feeling of discomfort or illness
  • irregular heartbeat
  • irritability
  • nausea
  • numbness of feet, hands and around mouth
  • restlessness
  • seeing double
  • sensation of spinning
  • sleepiness or unusual drowsiness
  • thoughts of killing oneself
  • trouble sleeping
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • unusually deep sleep
  • unusually long duration of sleep

Less common

  • Shakiness and unsteady walk
  • uncontrolled eye movements
  • unsteadiness, trembling, or other problems with muscle control or coordination

Incidence not known

  • Cough
  • difficulty breathing or swallowing
  • fever
  • hives
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • noisy breathing
  • reddening of the skin, especially around the ears
  • swelling of the eyes, face, or inside of the nose

Some side effects of brivaracetam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Difficulty having a bowel movement
  • vomiting

For Healthcare Professionals

Applies to brivaracetam: intravenous solution, oral liquid, oral tablet

General

The more commonly reported adverse events have included somnolence/sedation, dizziness, fatigue, and nausea/vomiting.

Nervous system

Very common (10% or more): Somnolence/sedation (up to 27%), dizziness and disturbances in gait and coordination (up to 16%); fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy)

Common (1% to 10%): Cerebellar coordination and balance disturbances, convulsion, vertigo

This drug causes dose-dependent increases in somnolence and fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy). In clinical trials, somnolence and fatigue-related adverse reactions were reported in 25%, 20%, 26%, and 27% of patients receiving at least 50 mg/day, 50 mg/day, 100 mg/day, and 200 mg/day, respectively. Adverse reactions related to dizziness, gait and coordination disturbances including vertigo, ataxia, nystagmus occurred in 16% of patients.

Psychiatric

Common (1% to 10%): Depression, anxiety, insomnia, irritability

Uncommon (0.1% to 1%): Suicidal ideation, psychotic disorder, aggression, agitation

Psychiatric adverse events have been commonly reported. During clinical trials, approximately 13% of patients (compared to 8% on placebo) reported psychiatric events which included irritability, anxiety, nervousness, aggression, belligerence, anger, agitation, restlessness, depression, depressed mood, tearfulness, apathy, altered mood, mood swings, affect lability, psychomotor hyperactivity, abnormal behavior, adjustment disorder, psychotic disorder, hallucinations, paranoia, acute psychosis and psychotic behavior. A total of 1.7% of adult patients discontinued treatment because of psychiatric reactions (compared to 1.3% of placebo). In pediatric trials, psychiatric events were generally similar.

Local

Common (1% to 10%): Infusion site pain

Hypersensitivity

Frequency not reported: Hypersensitivity, bronchospasm, angioedema

Metabolic

Common (1% to 10%): Decreased appetite, decreased weight

Hematologic

Common (1% to 10%): Decreased WBC

Uncommon (0.1% to 1%): Neutropenia

In clinical trials, at least 1.8% of patients had at least 1 clinically significant decreased WBC (compared to 1.1% of placebo).

Gastrointestinal

Common (1% to 10%): Nausea, vomiting, constipation

Respiratory

Common (1% to 10%): Upper respiratory tract infections, cough

Immunologic

Common (1% to 10%): Influenza

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Briviact (www.drugs.com/briviact.html).